Neoadjuvant concurrent chemoradiotherapy with and without hyperthermia in retroperitoneal sarcomas: feasibility, efficacy, toxicity, and long-term outcome

dc.contributor.authorWillner, A.
dc.contributor.authorFechner, K.
dc.contributor.authorAgaimy, A.
dc.contributor.authorHaller, F.
dc.contributor.authorEckstein, M.
dc.contributor.authorOtt, O. J.
dc.contributor.authorPutz, F.
dc.contributor.authorGaipl, U. S.
dc.contributor.authorKersting, S.
dc.contributor.authorMeidenbauer, N.
dc.contributor.authorGrützmann, R.
dc.contributor.authorFietkau, R.
dc.contributor.authorSemrau, S.
dc.date.accessioned2023-03-30
dc.date.available2023-10-09T21:18:03Z
dc.date.created2021
dc.date.issued2023-03-30
dc.description.abstractPurpose Retroperitoneal (RPS) sarcomas are associated with poor local and abdominal tumor control. However, the benefit of preoperative radio- or chemotherapy alone for these entities is currently unclear. Moreover, as intermediate- and high-grade sarcomas have a tendency toward early metastasis, exploration of neoadjuvant strategies is of high importance. This analysis reports the results of our 20-year single-institution experience with preoperative neoadjuvant concurrent chemoradiation. Methods From 2000–2019, 27 patients with intermediate- or high-grade RPS (12 dedifferentiated liposarcoma, 10 leiomyosarcoma, 5 others) were treated with radiotherapy (median dose: 50.4 Gy; range 45–75 Gy) and two cycles of chemotherapy (doxorubicin 50 mg/m2 BSA/d3 q28 and ifosfamide 1.5 g/m2 BSA/d1‑5 q28) in neoadjuvant intent. Chemotherapy consisted of doxorubicin alone in two cases and ifosfamide alone in one case. Fifteen patients (56%) additionally received deep regional hyperthermia. Results The median follow-up time was 53 months (±56.7 months). 92% of patients received two cycles of chemotherapy as planned and 92% underwent surgery. At 5 and 10 years, abdominal-recurrence-free survival was 74.6% (±10.1%) and 66.3% (±11.9%), distant metastasis-free survival was 67.2% (±9.7%) and 59.7% (±11.1%), and overall survival was 60.3% (±10.5%) and 60.3% (±10.5%), respectively. CTC grade III and IV toxicities were leukocytopenia (85%), thrombocytopenia (33%), and anemia (11%). There were no treatment-related deaths. Conclusion Neoadjuvant chemoradiotherapy with and without hyperthermia for retroperitoneal sarcomas is feasible and provided high local control of intermediate- and high-grade sarcoma.en
dc.format.extent8
dc.identifier.citationStrahlentherapie und Onkologie 197.12 (2021): S. 1063-1071. <https://link.springer.com/article/10.1007/s00066-021-01830-0>
dc.identifier.doihttps://doi.org/10.1007/s00066-021-01830-0
dc.identifier.issn0179-7158
dc.identifier.issn1439-099X
dc.identifier.opus-id22182
dc.identifier.urihttps://open.fau.de/handle/openfau/22182
dc.identifier.urnurn:nbn:de:bvb:29-opus4-221823
dc.language.isoen
dc.publisherSpringer Berlin Heidelberg
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/deed.de
dc.subjectThermotherapy
dc.subjectDoxorubicine
dc.subjectIfosfamide
dc.subjectLiposarcoma
dc.subjectLeiomyosarcoma
dc.subject.ddcDDC Classification::6 Technik, Medizin, angewandte Wissenschaften :: 61 Medizin und Gesundheit :: 610 Medizin und Gesundheit
dc.titleNeoadjuvant concurrent chemoradiotherapy with and without hyperthermia in retroperitoneal sarcomas: feasibility, efficacy, toxicity, and long-term outcomeen
dc.typearticle
dcterms.publisherFriedrich-Alexander-Universität Erlangen-Nürnberg (FAU)
local.date.prevpublished2021-12-01
local.document.pageend1071
local.document.pagestart1063
local.journal.issue12
local.journal.titleStrahlentherapie und Onkologie
local.journal.volume197
local.sendToDnbfree*
local.subject.fakultaetMedizinische Fakultät
local.subject.importimport
local.subject.sammlungUniversität Erlangen-Nürnberg / Eingespielte Open Access Artikel / Eingespielte Open Access Artikel 2023
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
22182_s00066-021-01830-0.pdf
Size:
1.25 MB
Format:
Adobe Portable Document Format
Description: